Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie
Introduction
Uveal melanoma is the most common primary ocular malignancy in the adult caucasian population and once metastases occurs the liver is the sole organ involved in 60–80% of cases.1, 2, 3 When liver metastases develop, the prognosis is poor and life expectancy reduces to less than 6 months in the absence of treatment.4 No adjuvant therapy has proven efficacy for the prevention of metastases following ocular treatment and only minimal improvements in disease-free survival have been observed with intra-arterial chemotherapy.5
The best survival rates with established liver metastases have been obtained with maximal tumour reduction, where technically possible.6, 7 Disseminated, or ‘miliary’, metastases are a very poor prognostic factor, frequently diagnosed only at the time of operation as current imaging methods (abdominal ultrasonography, computed tomography) are insufficiently sensitive to reliably exclude their presence pre-operatively.
The aim of this study was a long-term (16 years) review of the surgical management of liver metastases from uveal melanoma in a single institution with regard to survival and the determination of predictive factors for the optimal surgical candidate.
Section snippets
Patient selection
After primary ocular treatment, surveillance combined clinical ophthalmologic examination and abdominal ultrasonography (US) every 6 months. If metastases were suspected, hepatic computed tomography (CT) and/or magnetic resonance imaging (MRI) scanning was performed to both confirm the diagnosis and evaluate the feasibility of resection. The presence of lung metastases was evaluated pre-operatively initially by chest X-ray and more recently by CT. Pre-operative liver biopsy was performed, where
Results
During the study period 255 patients underwent hepatic surgery with a mean age of 56 years (range 19–81) and 133 were male. The median time between primary tumour diagnosis and hepatic surgery was 68 months (1–96). Only 13 patients had synchronous liver metastases.
Discussion
At our institution we developed an aggressive surgical approach to hepatic metastases of uveal melanoma. Initially, we undertook surgical exploration in all patients, but laparoscopic evaluation was not available and, due to the dissemination of the disease in the majority of patients, survival was almost uniformly poor. With increasing experience and improvements in hepatic imaging, we felt that the selection of patients for liver resection could be optimised by the prognostic features
Conclusion
Our results strongly support the notion that hepatic resection for liver metastases from uveal melanoma offers a greatly improved long-term survival in carefully selected patients. Important survival indicators include the time to metastases, the number and comprehensiveness of resected metastases, and the presence or absence of miliary disease.
Conflict of interest
The authors state that they have no conflict of interest.
Acknowledgements
We are grateful to Professor J. Belghiti for his scientific advice.
References (15)
- et al.
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
Ann Oncol
(2006) - et al.
Treatment of liver metastases from uveal melanoma by combined surgery–chemotherapy
Eur J Surg Oncol
(1998) - et al.
Prognostic factors for malignant uveal melanoma. Retrospective study on 2241 patients and recent contribution of monosomy-3 research
J Fr Ophthalmol
(2006) - et al.
Survival in metastatic ocular melanoma
Cancer
(1983) - et al.
Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up
Acta Ophtalmol Scand
(1995) - et al.
Variates of survival in metastatic uveal melanoma
J Clin Oncol
(2005) - et al.
Survival of patients with metastases from uveal melanoma
Ophthalmology
(1991)